Cantourage Group SE

News

30.10.2025 10:08:23
EQS-News: Q3 2025: Cantourage delivers strong operating performance in a challenging regulatory market environment
15.10.2025 15:49:13
EQS-News: Cabinet decision on the Medical Cannabis Act meets broad criticism / Cantourage expects changes and prepares to expand its “Telecan” platform
08.10.2025 13:01:02
EQS-News: Cantourage is responding to potential developments resulting from new legal regulations with focused internationalization and strategic product diversification
01.10.2025 09:47:53
EQS-News: Cantourage Strengthens Capital Markets Presence: New Head of Investor Relations and Strategic Focus on Europe
01.10.2025 09:39:05
EQS-DD: Cantourage Group SE: Philip Schetter, Acquisition of 188,639 Shares as Part of a Capital Increase Against Contributions in Kind, Excluding Subscription Rights, at an Issue Price of EUR ...
05.09.2025 09:00:10
Original-Research: Cantourage Group SE (von NuWays AG): BUY
11.07.2025 09:00:13
Original-Research: Cantourage Group SE (von NuWays AG): BUY
20.05.2025 07:51:53
EQS-News: Cantourage achieves strong and profitable growth in the first quarter of 2025
20.05.2025 07:46:40
EQS-Adhoc: Ad hoc: Cantourage significantly increases profitability and revenue – EBITDA margin of 11 to 13% in the first quarter of 2025
19.05.2025 09:00:15
Original-Research: Cantourage Group SE (von NuWays AG): BUY

Downloads

Latest Research
Initiation

Analyst

Christian Sandherr

Equity Research Analyst

MailLinkedIn

Latest Research

Christian Sandherr

05 Sep 25

Regulatory uncertainty and oversupply weighing on momentum

Update
Christian Sandherr

11 Jul 25

Ongoing strong operations, CEO with temporary personal leave

Update
Christian Sandherr

19 May 25

Growth further accelerating, € 100m sales in reach; chg.

Preview / Review
Christian Sandherr

14 Apr 25

Growth beating expectations, again; PT up

Preview / Review
Christian Sandherr

11 Mar 25

Q1 on track to hit a new record

Update

Best-in-class research on selected German and European small caps. Immediately at publication and 100% free of charge.

To learn how we process your data, visit our Privacy Notice.